Ir para o conteúdo principal

Cyclerion Therapeutics (NYSE: CYCN) — Perfil da empresa, notícias e dados financeiros

Logo de Cyclerion Therapeutics
CYCN Cyclerion Therapeutics
Cyclerion Therapeutics primary media
Perfil da empresa

Cyclerion Therapeutics

Cyclerion Therapeutics (NASDAQ:CYCN) focuses on discovering, developing, and commercializing innovative medicines for the treatment of serious diseases. The company is engaged in advancing a diverse pipeline of treatments that address central nervous system (CNS) disorders, including cognitive impairment and neurodegenerative conditions. Their objective is to leverage their unique scientific platform to bring breakthrough treatments to patients in need, aiming to improve lives through novel therapeutics. With a commitment to science and innovation, Cyclerion Therapeutics is dedicated to pushing the boundaries of medicine to tackle some of the most challenging health issues.

Resumo

Public USParticipação acionária
2018Ano de fundação
14Funcionários
Massachusetts, United StatesSede
Carregando mapa...
Presença global

Operações

Todos os locais
United States

Produtos e/ou serviços de Cyclerion Therapeutics

  • Development of treatments targeting the soluble guanylate cyclase (sGC) pathway for various diseases including heart, lung, and kidney disorders.
  • Research on central nervous system (CNS) therapies, focusing on cognitive impairment associated with schizophrenia and other neurological conditions.
  • Investigation into treatments for serious orphan diseases by leveraging the sGC stimulator platform to address unmet medical needs.
  • Initiatives aimed at advancing cardiovascular health, such as potential therapies for heart failure and hypertension through the modulation of sGC.
  • Exploration of novel therapeutic approaches in metabolic disorders, including diabetes and obesity, by targeting key pathways influencing metabolism.
  • Pursuit of the development of first-in-class treatments for genetic diseases affecting the nervous system, emphasizing rare and severe conditions.

equipe executiva do Cyclerion Therapeutics

  • Dr. Regina M. Graul Ph.D.CEO, President & Director
  • Ms. Rhonda M. Chicko CPAChief Financial Officer

Principais indicadores financeiros

Resultados divulgados pela Cyclerion Therapeutics, em USD.

Receita e lucro anuais da Cyclerion Therapeutics
Fim do ano fiscalReceitaResultado operacionalLucro líquido
2,1 mi-5 mi-3,5 mi
2 mi-3,6 mi-3,1 mi
0-13 mi-5,3 mi
297 mil-18,5 mi-44,1 mi